Member Info for Steadydanny

The BOD would not have drawn up the later subscriptions for the last 2 HNWIs if they were not confident that they were worth that amount. He even mentioned it in the Q and A.

It's not about covid. It's about what causes cytotoxicity and cytokine storms. And how those injected are required a treatment.

Gunner. Research is key Q and A was key.
To those not really understanding just listen to these extracts if you have the time.
In minutes re Q and A. Just focus on these
14 to 1450
1630 to 1639
2030 to 2115
2140 to 2330
2423 to 2435
And then 2715 to 2724!
2820 to 2905
3127 to 3135
3350 to 3410
And finally 3645 to 3740.
Just listen to their comments!

Not just restating my considerations that 737 got more news in our RNSs before the Q and A and then the update!!
11/12/2021

SAN MATEO, Calif.--(BUSINESS WIRE)-- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in the 2021 Jefferies London Healthcare Conference. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 8:00 am GMT (3:00 am ET) on Thursday, November 18, 2021, to conference attendees.
Now we are all here for a reason. Positive potential investment strategy based on great and informative posters and company strategy that see we have not only positive indicators but actual unique ipr.. That's why I partook.
Now the fireside conference I mentioned(check my posts) that 737 was not a dead duck. It got mentioned. And see what happened.
Our Q and A seems rather relevant! Re 737 !
Just in brief I'm waiting for another update re this conference.
Best regards Steadydanny

And this USPTO
25 March 2021
U.S. patent application number 17/108266 was filed with the patent office on 2021-03-25 for pharmaceutical compounds. This patent application is currently assigned to Sareum Limited. The applicant listed for this patent is Sareum Limited. Invention is credited to John Charles READER
Then this
Equivalents

[0509] The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitation on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.
When the penny drops.
READ IT ATLEAST 3 TIMES. SLOWLY .
The dates I mentioned. The timelines. The re negotiation. The cover. The noteable 737 mention increase in Sareum RNSs. The 1801 able to progress by ourselves. The 1802 similar rapid progress due to similarity and 'same initial pathways'.
Remember a submerged submarine patent when partially released...any future competitve approved products have a very very hard time to prove they did not 'borrow' the patent. We receive payments and royalties.
Sorry for barking on. I am so perplexed this is not being shouted out by our BODS via ndas. Unless they have been busy since March and we get Edison and HNWIs and wombles and hang on Perl Hunt into the equation.
Off to read Wilber Smith in bed.
Best regards Steadydanny

Also worth noting this extract from September 2016 RNS
PNT737 was originally developed in a research collaboration between the Institute of Cancer Research, London (ICR), Sareum Limited and Cancer Research Technology Ltd (CRT). The Programme was licensed to the CRT Pioneer Fund in September 2013 and a co-investment partnership with Sareum was formed to progress the candidate drug through clinical trials.  

Dr Tim Mitchell, CEO of Sareum commented, “This is a major achievement for our lead candidate as well as for Sareum.  Starting with the initial discovery, we have contributed financially and scientifically to the ongoing development of the programme into clinical trials. The returns from this research investment will be realised in this licence agreement, validating our strategy and business model.  ProNAi is in a strong position to further the development of PNT737 and plans to expand its development into the United States and with broader clinical studies.  We look forward to reporting on their progress.”
Well Pronai are now as we all know.....and about 5 years are deemed worthy of approval of a watertight patent ....and when was the document that someone raised here re submarine patent....was it possibly around April 2021?
Food for thought. We have a licence agreement in place which was recently tweaked and have imo worked on this further.
Sincerely I was going to say this morning I would see a significant jump in price as imo the fundamentals suggest it should. The rise today is just not befitting.
Imo etc

This is from NHS HRA 25th April 2016. Re 737 and sponsored by Sierra. Which is in joint collaboration with Sareum, ICR and CRT. So just over 5 years ago. I maybe reading too much into it but I'm getting doseage considerations that were mentioned back then and wondering about our submarine patent news recently (join the dots) and Tim's positive upbeat in Q and A re Sierras 100% lung cancer result. Here it is
SRA737 is a type of drug called a kinase inhibitor. It blocks a chemical messenger (enzyme) called checkpoint kinase 1 (CHK-1) which is part of the signalling process within cells. This can make cells produce chemicals that trigger and control cell growth and cell death. In some types of cancer these chemical messengers are 'switched on' or ‘switched off’ allowing the cancer cells to keep growing and to grow more quickly than normal cells. Kinase inhibitors are a new type of drug being used to try to stop the growth of cancers and to kill cancer cells.
The main aims of this clinical study are to find out:
• The maximum dose that can be given safely to patients;
• More about the potential side effects of the drug and how they can be managed;
• What happens to drug inside the body; and
• Whether the drug has an effect on the cancer and whether the effect, if any, is related to specific changes in the tumour’s DNA.

This information will help us decide how much and how often to give SRA737 to patients in future studies. It may also help us understand any effect the drug may have on cancer.

I am feeling something rather very significant is going to be revealed. The world will hear about it?
Imo etc

I agree we are waiting on the toxicology report which I'm expecting soon, and possibly more before Xmas.
Also re the doom mongers this is from the Q and A...not verbatim but it was what Tim said just listen to it!
JAK market 2020 £18b. £320b by 2026.
Enough money to pursue complete trials of 1801
Then re 1802 expect rapid advancement due to the similarities to 1801...as very similar and the same initial pathway
Note recent US patent upgrade for further protection.
Re TYK2 the response was pretty much ...not concerned about being first to market for TYK2 applications, as we will be first!
Which he added has potential for multiple diseases.
737 update 100% positive response re lung cancer. That was a moment if people listened to it...he was rather excited.
So we can hold our own for quite sometime and continue to add value as per our corporate objectives stipulate.
And that armchair report ...the bit i got from it was he actually justified the sp rise to record high hence we wouldn't have have received the later subscriptions.
So upto each individual to see the news for what it is. Very Positive imo!
Peel Hunt are not brought in for a picnic. They are here to act on our behalf and negotiate on our behalf with their expertise.
I'm wondering if the gameplay and greatly improved funding is that potential licencees are that we have placed ourselves as not the poor relative but someone who has a stronger negotiating platform. So we can go forward or they can make us offers.
Jerry Maguire springs to mind...show me the money!!
Regards Steadydanny

Probably get banned for this. Not fussed. As I said I'm here re cytokine storms. Check out DM re Pfizer misreporting and in other news their CEOs wife. Very concerning.

SOG. Yes yes and yes. Completely agree with your opinion/s.
This was very telling from a recent RNS.
Sareum's CSO, Dr John Reader, commented:

"We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones."
When he mentions 'key territories' the submarine patent pretty much covered the world.
The 'news' reports re Sareum are so biased. They never ever mention progress made which didn't require a public funding as it got private funding post Edison report and literally ignore potential contract obligations re 737 and our recent Q and A personally mind blowing 737 comment. Et al !
And didn't we have some posters try to twist the RNSs.
I read somewhere if you are of worth and the late jealous types are late to the table they will try their best to ridicule you and undermine you for their benefit. Bit of a Tom Sawyer perspective.

I believe if you make the initial findings public without stating the specifics and then 'submerge' the patent application without it being 'granted' then any 'competitor' who 'creates' an approved product using your temporary emerged patent 'released' findings will owe them royalties et al. And I believe it is very very hard for the 'competitor' to prove otherwise that they are not utilising others workings and findings.
So it's like we shine a light on a technique/method we have invented to wet their whistles. I assume that's when the behind doors discussions and licensing details occur.

Good shout.

Ahfam what do you mean by giving it a go? Seriously what do you mean?

Hi Ahfam. It's not about myself having a go. It's literally and specifically about a noted negative amount of posting here. Recently. And remember Slyhuntress and senator before we got the Edison report and HNWI investment?
Personally I don't give a ff for some of the comments here.
Just posting my thoughts. And I like to think i am Aware of the details in our RNSs.

Still waiting for a considered response to dispose the value sareum have and are attributable to re an unplaced consideration. Come on give it your best shot.

Basser1. Completely agree. Seems some are scared of responding to the trolls as their responses are a bit aggressive in reasons in disputing reasons to invest.. I'm not surprised as the trolls are a collective. I wish one of them would respond to me directly for my considered response.
Please naysayers re sareum please ask me directly why sareum is not a good/ great investment.

Spot on Mafuta. And this from 23rd April this year. If only people 'invested' that haven't read the RNSs. Especially this one .Seriously please anyone who is invested with dd probably get this but those who are questionable in posting I ask to read this and see the HNWI investors the submarine patent and solubility etc etc fgs this is an awakening previously
OPERATIONAL HIGHLIGHTS (including post-period updates)

Proprietary Programmes - Selective TYK2/JAK1 Inhibitors

SDC-1801 (autoimmune diseases and severe Covid-19)

· The Company has made substantial progress despite the challenges of the Covid-19 pandemic

· Completed dose range finding studies in two preclinical toxicology species

· New formulation designed to deliver higher exposure levels found to be well-tolerated

· UK Research & Innovation grant of £174,000 awarded in December 2020 for six-month research project to investigate therapeutic potential of SDC-1801 in severe phase Covid-19, with results expected mid-year 2021

· Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2

· Exploratory Clinical Trial Application ("CTA") expected to be filed mid-year 2021 subject to successful completion of final toxicity and safety studies

SDC-1802 (cancer immunotherapy)

· Designing translational studies to define the optimal cancer application prior to completing toxicology and manufacturing studies

· US patent (US 10,882,829) granted in January 2021 completes patent protection for SDC-1802 in the US and across all major territories

Licensed Programmes

SRA737: A Selective Chk1 inhibitor (solid cancers)

· Sierra Oncology, Inc. ("Sierra") and CRT Pioneer Fund LP ("CPF") amended their 2016 licensing agreement for SRA737: revised milestone schedule includes $2.0 million payment upon the dosing of the first patient in the next clinical trial, and slightly reduced overall outstanding milestones payable by Sierra

· Sareum remains eligible to receive 27.5% of the economics of the Licence Agreement

· Sierra continues to explore internal and external options for continuing development and Sareum believes that the licensing agreement amendment will prove important in expediting this development

FLT3+Aurora Inhibitors (haematological cancers)

· Licensing partner for FLT3+Aurora kinase inhibitor programme discontinued development as it was unable to achieve required bioavailability and returned worldwide rights to Sareum
I'm at a loss if real investors can't see what has been mentioned back then and then the updates we have had.
We are being trolled.

X violet you would benefit from reading our website as you seem to throw a bit of consternation and doubt on here which you could alleviate your procrastination. Here's a bit that might help.

Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

ApproachBenefit
Pursue multiple programmes
Increase potential success rate
Mitigate development risk
Seek collaboration partners
Spread financial cost and risk
Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

Minimise ongoing development risk
Move up value chain
Potential for higher deal values

Where this is on our website has other great information available too.

Hi Mafuta hope all is well. I would like to say that I was never surprised by the 737 update. It was implied in our previous RNSs. I mentioned it numerous times prior to our Q and A update. My previous posts support that without doubt. Despite being told it was a no goer. That's also why I reckon we will get a FLT3 update soonish.
Regards Steadydanny

Hi Lazarus. Firstly I respect and enjoy your posts. I think we are on a similar hymn sheet. Yes 737 is definitely looking rather marvellous and this extract I refer to
The out-licensed assets, SRA737 and FLT3+Aurora kinase, are currently de-prioritised but offer upside potential on revived activity.
Revived activity.....so 737 shows 100% response re cancer and Tim was very definitely excited.
FLT3 next? I think so. Revived activity! That says to me that activity re FLT3 is occuring and ongoing and we will get to know.
Best regards Steadydanny